Drug dosing for renoprotection: Maybe it's time for a drug efficacy-safety score?

Journal of the American Society of Nephrology

Volumn 20, Issue 4, 2009, Pages 688-689

  De Zeeuw, Dick ^a   Lambers Heerspink, Hiddo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ALBUMINURIA; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

EID: 65249092565     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009020172     Document Type: Editorial

References (9)

1. For USA standards: http://www.fda.gov/Cder/Offices/OPS-IO/MRTD. htm. Accessed March 19, 2009
2. Hoorntje SJ, Kallenberg CG, Weening JJ, Donker AJ, The TH, Hoe-demaeker PJ: Immune-complex glomerulopathy in patients treated with captopril. Lancet 1: 1212-1215, 1980
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N EnglJ Med 329: 1456-1462, 1993
4. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18: 1540-1546, 2007
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbu- minuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
6. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, KawamoriR, Takeuchi M, Katayama S, INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30: 1577-1578, 2007
7. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18: 1889-1898, 2007
8. Burgess E, Muirhead N, de Cotret PR, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Neph-rol 20: 893-900, 2009
9. Konstam MA, Poole-Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GA, Guptha S: Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Eur J Heart Fail 10: 899-906, 2008